Metabolomics as a diagnostic tool for idiopathic non‐cirrhotic portal hypertension
Metabolomics as a diagnostic tool for idiopathic non‐cirrhotic portal hypertension
复制标题
DOI：
10.1111/liv.12972
复制
发表时间：
2016-07
影响因子：
6.7
通讯作者：
S. Seijo;J. Lozano;C. Alonso;R. Miquel;A. Berzigotti;E. Reverter;F. Turon;M. Martínez‐Chantar;A. Castro;J. Mato;V. Hernández-Gea;J. Bosch;J. García‐Pagán
中科院分区：
文献类型：
--
作者：
S. Seijo;J. Lozano;C. Alonso;R. Miquel;A. Berzigotti;E. Reverter;F. Turon;M. Martínez‐Chantar;A. Castro;J. Mato;V. Hernández-Gea;J. Bosch;J. García‐Pagán
特发性非肝硬化性门脉高压症（INCPH）是一种罕见的危及生命的肝脏疾病，缺乏特异性诊断测试，经常被误诊为隐源性肝硬化。我们小组的初步数据确定了血浆代谢组学特征，能够区分INCPH与肝硬化患者（CH）和健康志愿者（HV）。然而，应用的非靶向方法无法识别所有特定代谢物，阻碍了建立诊断模型的可能性。本研究通过高通量代谢组学技术广泛应用了先前鉴定的代谢物，评估是否存在允许非侵入性诊断INCPH的代谢组学特征。
Idiopathic non‐cirrhotic portal hypertension (INCPH) is a rare life‐threatening liver disease that lacks a specific diagnostic test being frequently misdiagnosed as cryptogenic cirrhosis. Preliminary data from our group identified a plasma metabolomic profile able to differentiate INCPH from patients with cirrhosis (CH) and healthy volunteers (HV). However, the untargeted methodology applied was unable to identify all the specific metabolites, hampering the possibility of building‐up diagnostic models. This study applies a wide‐coverage of previously identified metabolites through a high‐throughput metabolomics technology, evaluating if there is a metabolomic profile that allows a non‐invasive diagnosis of INCPH.